ERBB2 and breast carcinoma: For instance, the Visiopharm company claims that their HER2 IHC algorithm reduces the 2+ category, comprising about 20% of breast cancer cases and for which expensive reflex FISH testing is indicated, by some 75%, which would amount to saving €3600 per 100 random breast cancer cases.